Reducing adverse drug events in the outpatient chemotherapy setting

Attention must be paid


  • Jonathan R. Nebeker M.S., M.D.,

    Corresponding author
    1. Geriatric Research Education and Clinical Center (GRECC) and Salt Lake Informatics Decision Enhancement and Surveillance (IDEAS) Center, George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, Utah
    2. Department of Medicine, University of Utah, Salt Lake City, Utah
    • George E. Wahlen Veterans Affairs Salt Lake City Health Care System, University of Utah, GRECC 182, 500 Foothill Drive, Salt Lake City, UT 84148
    Search for more papers by this author
    • Fax: (801) 584-5640

  • Charles L. Bennett M.D., Ph.D., M.P.P.

    1. Mid-West Center for Health Services and Policy Research and Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois
    2. Department of Medicine, the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
    Search for more papers by this author

  • See referenced original article on pages 2477–83, this issue.


Cancer agents have the potential for severe, and occasionally fatal, adverse drug events. Many receive accelerated approval for use after small clinical trials, with adverse drug events being identified after additional experience in the postmarketing clinical setting. Moreover, chemotherapy risks may be especially high in tertiary care settings where patients are frequently subject to complex treatment protocols with high dosages, novel agents, or novel combinations of agents. Recommendations from the study on medication errors by Gandhi et al. contribute to international efforts to prevent adverse drug reactions and improve their early recognition and treatment.

See also pages 2477–83.